Change in biomarkers of type-2 inflammation following severe exacerbations of asthma
We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×109/L, p
Gespeichert in:
| Veröffentlicht in: | Thorax 2019-01, Vol.74 (1), p.95-98 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 95 |
| container_title | Thorax |
| container_volume | 74 |
| creator | Semprini, Ruth Shortt, Nick Ebmeier, Stefan Semprini, Alex Varughese, Rachel Holweg, Cecile T J Matthews, John G Fingleton, James Weatherall, Mark Beasley, Richard Braithwaite, Irene |
| description | We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×109/L, p |
| doi_str_mv | 10.1136/thoraxjnl-2018-211657 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2072183781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2156346528</sourcerecordid><originalsourceid>FETCH-LOGICAL-b533t-9752a091b4ec0104038e17da3587ccea9fe4476458ae9970d88f6d54128d0a483</originalsourceid><addsrcrecordid>eNqNkEtr3DAUhUVJaCZJf0KLIZtu3Nyrt5dlaJtAIJtkLWT7esZT25pKnjz-fTyZ6RS6CFkJpO8cjj7GPiN8QxT6clyG6J9WQ5dzQJtzRK3MBzZDqW0ueKGP2AxAQq6F0SfsNKUVAFhE85GdCACOFmHG7uZLPywoa4esbEPv42-KKQtNNj6vKefTfdP5vvdjG4asCV0XHtthkSV6oEgZPfmKYvn6-pryaVz2_pwdN75L9Gl_nrH7nz_u5lf5ze2v6_n3m7xUQox5YRT3UGApqQKctgpLaGovlDVVRb5oSEqjpbKeisJAbW2jayWR2xq8tOKMfd31rmP4s6E0ur5NFXWdHyhskuNgpm8KY3FCL_5DV2ETh2md46i0kFrxbaHaUVUMKUVq3Dq2k5Rnh-C22t1Bu9tqdzvtU-7Lvn1T9lQfUn89TwDsgLJfvbsT_0UOY9_OvADLl582</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2156346528</pqid></control><display><type>article</type><title>Change in biomarkers of type-2 inflammation following severe exacerbations of asthma</title><source>Alma/SFX Local Collection</source><creator>Semprini, Ruth ; Shortt, Nick ; Ebmeier, Stefan ; Semprini, Alex ; Varughese, Rachel ; Holweg, Cecile T J ; Matthews, John G ; Fingleton, James ; Weatherall, Mark ; Beasley, Richard ; Braithwaite, Irene</creator><creatorcontrib>Semprini, Ruth ; Shortt, Nick ; Ebmeier, Stefan ; Semprini, Alex ; Varughese, Rachel ; Holweg, Cecile T J ; Matthews, John G ; Fingleton, James ; Weatherall, Mark ; Beasley, Richard ; Braithwaite, Irene</creatorcontrib><description>We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×109/L, p<0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p<0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p<0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.Trial registration numberPost-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thoraxjnl-2018-211657</identifier><identifier>PMID: 30021810</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Asthma ; Biomarkers ; Brief communication ; Inflammation ; Nitric oxide</subject><ispartof>Thorax, 2019-01, Vol.74 (1), p.95-98</ispartof><rights>Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b533t-9752a091b4ec0104038e17da3587ccea9fe4476458ae9970d88f6d54128d0a483</citedby><cites>FETCH-LOGICAL-b533t-9752a091b4ec0104038e17da3587ccea9fe4476458ae9970d88f6d54128d0a483</cites><orcidid>0000-0001-5327-3027 ; 0000-0001-5449-0744 ; 0000-0001-9148-196X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30021810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Semprini, Ruth</creatorcontrib><creatorcontrib>Shortt, Nick</creatorcontrib><creatorcontrib>Ebmeier, Stefan</creatorcontrib><creatorcontrib>Semprini, Alex</creatorcontrib><creatorcontrib>Varughese, Rachel</creatorcontrib><creatorcontrib>Holweg, Cecile T J</creatorcontrib><creatorcontrib>Matthews, John G</creatorcontrib><creatorcontrib>Fingleton, James</creatorcontrib><creatorcontrib>Weatherall, Mark</creatorcontrib><creatorcontrib>Beasley, Richard</creatorcontrib><creatorcontrib>Braithwaite, Irene</creatorcontrib><title>Change in biomarkers of type-2 inflammation following severe exacerbations of asthma</title><title>Thorax</title><addtitle>Thorax</addtitle><addtitle>Thorax</addtitle><description>We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×109/L, p<0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p<0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p<0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.Trial registration numberPost-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.</description><subject>Asthma</subject><subject>Biomarkers</subject><subject>Brief communication</subject><subject>Inflammation</subject><subject>Nitric oxide</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkEtr3DAUhUVJaCZJf0KLIZtu3Nyrt5dlaJtAIJtkLWT7esZT25pKnjz-fTyZ6RS6CFkJpO8cjj7GPiN8QxT6clyG6J9WQ5dzQJtzRK3MBzZDqW0ueKGP2AxAQq6F0SfsNKUVAFhE85GdCACOFmHG7uZLPywoa4esbEPv42-KKQtNNj6vKefTfdP5vvdjG4asCV0XHtthkSV6oEgZPfmKYvn6-pryaVz2_pwdN75L9Gl_nrH7nz_u5lf5ze2v6_n3m7xUQox5YRT3UGApqQKctgpLaGovlDVVRb5oSEqjpbKeisJAbW2jayWR2xq8tOKMfd31rmP4s6E0ur5NFXWdHyhskuNgpm8KY3FCL_5DV2ETh2md46i0kFrxbaHaUVUMKUVq3Dq2k5Rnh-C22t1Bu9tqdzvtU-7Lvn1T9lQfUn89TwDsgLJfvbsT_0UOY9_OvADLl582</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Semprini, Ruth</creator><creator>Shortt, Nick</creator><creator>Ebmeier, Stefan</creator><creator>Semprini, Alex</creator><creator>Varughese, Rachel</creator><creator>Holweg, Cecile T J</creator><creator>Matthews, John G</creator><creator>Fingleton, James</creator><creator>Weatherall, Mark</creator><creator>Beasley, Richard</creator><creator>Braithwaite, Irene</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ Publishing Group LTD</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5327-3027</orcidid><orcidid>https://orcid.org/0000-0001-5449-0744</orcidid><orcidid>https://orcid.org/0000-0001-9148-196X</orcidid></search><sort><creationdate>20190101</creationdate><title>Change in biomarkers of type-2 inflammation following severe exacerbations of asthma</title><author>Semprini, Ruth ; Shortt, Nick ; Ebmeier, Stefan ; Semprini, Alex ; Varughese, Rachel ; Holweg, Cecile T J ; Matthews, John G ; Fingleton, James ; Weatherall, Mark ; Beasley, Richard ; Braithwaite, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b533t-9752a091b4ec0104038e17da3587ccea9fe4476458ae9970d88f6d54128d0a483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Asthma</topic><topic>Biomarkers</topic><topic>Brief communication</topic><topic>Inflammation</topic><topic>Nitric oxide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Semprini, Ruth</creatorcontrib><creatorcontrib>Shortt, Nick</creatorcontrib><creatorcontrib>Ebmeier, Stefan</creatorcontrib><creatorcontrib>Semprini, Alex</creatorcontrib><creatorcontrib>Varughese, Rachel</creatorcontrib><creatorcontrib>Holweg, Cecile T J</creatorcontrib><creatorcontrib>Matthews, John G</creatorcontrib><creatorcontrib>Fingleton, James</creatorcontrib><creatorcontrib>Weatherall, Mark</creatorcontrib><creatorcontrib>Beasley, Richard</creatorcontrib><creatorcontrib>Braithwaite, Irene</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Semprini, Ruth</au><au>Shortt, Nick</au><au>Ebmeier, Stefan</au><au>Semprini, Alex</au><au>Varughese, Rachel</au><au>Holweg, Cecile T J</au><au>Matthews, John G</au><au>Fingleton, James</au><au>Weatherall, Mark</au><au>Beasley, Richard</au><au>Braithwaite, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Change in biomarkers of type-2 inflammation following severe exacerbations of asthma</atitle><jtitle>Thorax</jtitle><stitle>Thorax</stitle><addtitle>Thorax</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>74</volume><issue>1</issue><spage>95</spage><epage>98</epage><pages>95-98</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><abstract>We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×109/L, p<0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p<0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p<0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.Trial registration numberPost-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><pmid>30021810</pmid><doi>10.1136/thoraxjnl-2018-211657</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-5327-3027</orcidid><orcidid>https://orcid.org/0000-0001-5449-0744</orcidid><orcidid>https://orcid.org/0000-0001-9148-196X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-6376 |
| ispartof | Thorax, 2019-01, Vol.74 (1), p.95-98 |
| issn | 0040-6376 1468-3296 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2072183781 |
| source | Alma/SFX Local Collection |
| subjects | Asthma Biomarkers Brief communication Inflammation Nitric oxide |
| title | Change in biomarkers of type-2 inflammation following severe exacerbations of asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A22%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Change%20in%20biomarkers%20of%20type-2%20inflammation%20following%20severe%20exacerbations%20of%20asthma&rft.jtitle=Thorax&rft.au=Semprini,%20Ruth&rft.date=2019-01-01&rft.volume=74&rft.issue=1&rft.spage=95&rft.epage=98&rft.pages=95-98&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136/thoraxjnl-2018-211657&rft_dat=%3Cproquest_cross%3E2156346528%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2156346528&rft_id=info:pmid/30021810&rfr_iscdi=true |